Funding Opportunity RFA-OH-22-006 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to provide funding to municipalities, port authorities, other appropriate public entities, not-for-profit organizations, and other qualified persons to conduct commercial fishing vessel safety training for vessel operators and crewmembers.

Notice NOT-HG-22-028 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-22-050 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support computational dynamic modeling of molecular complexes regulating the HIV life cycle, immune responses, and therapeutic interventions in HIV/AIDS using existing and new HIV and HIV/host cell structural datasets.

Funding Opportunity PAR-22-208 from the NIH Guide for Grants and Contracts. The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2019 update to the National Plan to Address Alzheimer's Disease.

Funding Opportunity RFA-DA-23-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks grant applications from small business concerns (SBCs) to develop psychoplastogenic compounds and related models for drug discovery and drug development for Substance Use Disorders (SUD), excluding alcohol use disorder.

Notice NOT-TW-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-158 from the NIH Guide for Grants and Contracts

Notice NOT-AG-22-023 from the NIH Guide for Grants and Contracts

Notice NOT-AG-22-024 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-174 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.

Funding Opportunity PAR-22-173 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.

Funding Opportunity RFA-AG-23-033 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications seeking to develop novel, transformative artificial intelligence/machine learning (AI/ML) strategies, and computer automation, to integrate, extract, and interpret multi-omic (i.e., genome, epigenome, transcriptome, proteome, metabolome, microbiome, phenome) data sets from human exceptional longevity (EL) cohorts and multiple non-human species that display wide variation in life span and decipher the relationships between DNA, RNA, proteins, metabolites, and other cell variables, as well as links to disease risks and exceptionally healthy aging. The investigative team(s) for this FOA is/are expected to be multi-disciplinary, encompassing expertise in AI/ML and a variety of disciplines, including, but not limited to, aging biology, comparative biology, and bio/chemo informatics. This FOA utilizes the National Institutes of Health's Phased Innovation Award (R21/R33) funding mechanism. During the R21 phase, investigative teams will design and develop intelligent and innovative algorithms and novel AI/ML based computational strategies. During the R33 phase, teams will apply the developed AI/ML tools to complex, heterogenous multi-omic data sets from exceptional healthy aging human cohorts and non-human species to discover novel protective molecular factors that influence EL, and to develop translational strategies on omic based therapeutic target(s) to prevent, or delay, age-related diseases, including Alzheimers disease (AD) and AD-related dementia (ADRD), and enhance human health span.

Notice NOT-TR-22-032 from the NIH Guide for Grants and Contracts

Funding Opportunity PAS-22-196 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to the National Institute on Aging's (NIA) Small Business Innovation Research (SBIR) program. The aim of this FOA is to support research that may lead to the development of innovative products and/or services that have the potential to advance progress in preventing and treating Alzheimer's disease (AD) and AD-related dementias (ADRD) and/or caring for and treating patients living with AD/ADRD.

Notice NOT-OD-22-135 from the NIH Guide for Grants and Contracts

Notice NOT-DA-22-062 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-092 from the NIH Guide for Grants and Contracts

Notice NOT-DA-22-063 from the NIH Guide for Grants and Contracts

Notice NOT-DC-22-009 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-001 from the NIH Guide for Grants and Contracts